Development programme
REWIND — dulaglutide cardiovascular outcomes
A cardiovascular outcome trial notable for enrolling a majority primary-prevention population, which is unusual in this class and materially affects how its result generalises.
A cardiovascular outcome trial notable for enrolling a majority primary-prevention population, which is unusual in this class and materially affects how its result generalises.
Sponsor class: Manufacturer-sponsored. First record: 2011.
Showing 0 records on this page
Records in this programme
5 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| REWIND | Dulaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,901 | 2019 | High |
| REWIND-BIOMARKERprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| REWIND-QOLprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| REWIND-REGIONAL-CNprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| REWIND-REGIONAL-JPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |